SCHEMBL1589946

SCHEMBL1589946

COc1cc(C=Cc2nc3ccccc3c(=O)o2)ccc1OC(C)=O

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 8/20 0.71
▸ RAB9A P51151 7/20 0.71
▸ KMT2A Q03164 6/20 0.66
▸ MEN1 O00255 5/20 0.66
▸ HSP90AA1 P07900 1/20 0.66
▸ ELANE P08246 1/20 0.57
▸ JUN P05412 1/20 0.52
▸ NFKB1 P19838 1/20 0.52
▸ MAPT P10636 3/20 0.52
▸ ALDH1A1 P00352 4/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ VCP P55072 1/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ LMNA P02545 2/20 0.47
▸ ERO1A Q96HE7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1589944 1.00 NPC1 (0.71) NPC1RAB9AKMT2AMEN1HSP90AA1
SCHEMBL1590366 0.96 NPC1 (0.71) NPC1RAB9AKMT2AMEN1HSP90AA1
SCHEMBL1590369 0.96 NPC1 (0.71) NPC1RAB9AKMT2AMEN1HSP90AA1
SCHEMBL1589852 0.91 NPC1 (0.72) NPC1RAB9AKMT2AMEN1HSP90AA1
SCHEMBL1589854 0.91 NPC1 (0.72) NPC1RAB9AKMT2AMEN1HSP90AA1
SCHEMBL12723511 0.89 NPC1 (0.74) NPC1RAB9AKMT2AMEN1HSP90AA1
SCHEMBL12723510 0.88 NPC1 (0.72) NPC1RAB9AKMT2AMEN1HSP90AA1
SCHEMBL12723710 0.88 NPC1 (0.72) NPC1RAB9AKMT2AMEN1HSP90AA1
SCHEMBL134146 0.86 NPC1 (0.67) NPC1RAB9AKMT2AMEN1HSP90AA1
SCHEMBL12723717 0.85 NPC1 (0.70) NPC1RAB9AKMT2AMEN1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2947073-B1 FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS FIBROTECH THERAPEUTICS PTY LTD (AU) 2019-04-03 — — EP disclosed
US-9951087-B2 Fused ring analogues of anti-fibrotic agents FIBROTECH THERAPEUTICS PTY LTD (AU) 2018-04-24 — — US disclosed
EP-2947073-A2 FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS Fibrotech Therapeutics Pty Ltd (AU) 2015-11-25 — — EP disclosed
US-20150266893-A1 FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS FIBROTECH THERAPEUTICS PTY LTD (AU) 2015-09-24 — — US disclosed
EP-2491030-B1 FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS FIBROTECH THERAPEUTICS PTY LTD (AU) 2015-07-15 — — EP disclosed
US-9062076-B2 Fused ring analogues of anti-fibrotic agents FIBROTECH THERAPEUTICS PTY LTD (AU) 2015-06-23 — — US disclosed
US-20130338151-A9 FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS FIBROTECH THERAPEUTICS PTY LTD (AU) 2013-12-19 — — US disclosed
US-20120270863-A1 FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS FIBROTECH THERAPEUTICS PTY LTD (AU) 2012-10-25 — — US disclosed
EP-2491030-A1 FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS Fibrotech Therapeutics PTY LTD (AU) 2012-08-29 — — EP disclosed
WO-2011047432-A1 FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS FIBROTECH THERAPEUTICS PTY LTD (AU) 2011-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266893-A1 FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS MMP1, FIBP, COL2A1 NPC1 1936/4885RAB9A 2239/4885KMT2A 4025/4885
US-20120270863-A1 FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS MMP1, FIBP, COL2A1 NPC1 1936/4885RAB9A 2239/4885KMT2A 4025/4885
US-20130338151-A9 FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS MMP1, FIBP, COL2A1 NPC1 1936/4885RAB9A 2239/4885KMT2A 4025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback